Loading chat...
NH SB465
Bill
Status
3/16/2026
Primary Sponsor
William Gannon
Click for details
AI Summary
-
Classifies xylazine as a Schedule III controlled drug under New Hampshire's Controlled Drug Act (RSA 318-B)
-
Bypasses the standard rulemaking process by the Department of Health and Human Services commissioner for scheduling this substance
-
Effective date of January 1, 2027
-
Fiscal impact on state expenditures is indeterminable, with potential costs to judicial and correctional systems including prosecution, incarceration, probation, and parole
-
County and local expenditures are also indeterminable due to the new criminal penalty implications
Legislative Description
Classifying xylazine as a schedule III controlled drug.
Last Action
Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture House Journal 8
3/16/2026